Candel Therapeutics, Inc. (NasdaqGM: CADL)
Health Care · Biotechnology · US
$9.82
-3.54% today · +83.1% 1Y
Candel Therapeutics, Inc. (NasdaqGM: CADL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $778.96M and employs 55 people.
Over the last twelve months the share price has gained 83.1%, trading between 4.35 and 14.00.
Tweenvest scores Candel Therapeutics, Inc. across four factors: quality 37/100, value 74/100. Its strongest factor is value.
CADL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $778.96M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.44
- Dividend yield
- —
- Beta (5Y)
- -0.31
- 52-week high
- $14.00
- 52-week low
- $4.35
- Avg volume (3M)
- —
- Shares outstanding
- 76.52M
- Employees
- 55
- Next earnings
- —
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
- ISIN
- US1374041093
- Founded
- 2003
- Listed since
- Jul 27, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Inventiva S.A.ENXTPA: IVA | $836.35M | €3.15 | +10.54% |
| Sana Biotechnology, Inc.NasdaqGS: SANA | $814.26M | $2.72 | -1.09% |
| Ardelyx, Inc.NasdaqGM: ARDX | $812.35M | $3.26 | -1.51% |
| Immix Biopharma, Inc.NasdaqCM: IMMX | $802.50M | $9.49 | -1.96% |
| Geron CorporationNasdaqGS: GERN | $770.97M | $1.20 | -0.83% |
| Annexon, Inc.NasdaqGS: ANNX | $760.21M | $4.01 | -0.50% |
| Getein Biotech, IncSHSE: 603387 | $755.75M | CN¥10.01 | +1.93% |
| Gyre Therapeutics, Inc.NasdaqCM: GYRE | $753.90M | $7.04 | -0.98% |
Figures last refreshed Oct 4, 2026.